What is the 13F Pro Quality Score for LONA?

13F Pro ranks LeonaBio, Inc. (LONA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LONA's current score at https://13fpro.ai/research/LONA (free sign-up required for the full ranking).

Where does 13F Pro source LONA data?

All LeonaBio, Inc. fundamentals and ownership data come directly from SEC EDGAR. LeonaBio, Inc. files with the SEC under CIK 1620463. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LONA in?

LeonaBio, Inc. (LONA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LONA research updated on 13F Pro?

LONA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LeonaBio, Inc.(LONA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1620463 LONA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 38 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

LONA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LeonaBio, Inc. (LONA), a Healthcare sector company. LONA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 38 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), LeonaBio, Inc. reports net income of $-32.9M, free cash flow of $-20.9M. Top institutional holders of LONA by reported 13-F value include PERCEPTIVE ADVISORS, ADAR1 Capital Management,, ACORN CAPITAL ADVISORS,, based on the most recent SEC filings. LONA trades on the Nasdaq exchange and files with the SEC under CIK 1620463. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LONA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LeonaBio, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-32.9M

Free Cash Flow

Q1 2026

$-20.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+10.3% YoY

$-105.6MFY 2025

FY21 $-54.9MFY22 $-95.6MFY23 $-117.7MFY25 $-105.6M

Operating Income

+18.5% YoY

$-102.3MFY 2025

FY21 $-64.0MFY22 $-104.0MFY23 $-125.5MFY25 $-102.3M

EPS (Diluted)

-699.4% YoY

$-24.70FY 2025

FY21 $-1.49FY22 $-2.53FY23 $-3.09FY25 $-24.70

Total Assets

-42.5% YoY

$92.2MFY 2025

FY21 $332.0MFY22 $258.2MFY23 $160.2MFY25 $92.2M

Op. Cash Flow

+54.6% YoY

$-45.7MFY 2025

FY21 $-43.1MFY22 $-72.5MFY23 $-100.8MFY25 $-45.7M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-105.6M +10.3%	$-117.7M -23.0%	$-95.6M -74.4%	$-54.9M -174.9%	$-20.0M -286.6%	$-5.2M
Operating Income	$-102.3M +18.5%	$-125.5M -20.6%	$-104.0M -62.5%	$-64.0M -220.2%	$-20.0M -266.9%	$-5.4M
EPS (Diluted)	$-24.70 -699.4%	$-3.09 -22.1%	$-2.53 -69.8%	$-1.49	—	—
Total Assets	$92.2M -42.5%	$160.2M -37.9%	$258.2M -22.2%	$332.0M +18.8%	$279.6M +12671.3%	$2.2M
Operating Cash Flow	$-45.7M +54.6%	$-100.8M -39.0%	$-72.5M -68.1%	$-43.1M -78.7%	$-24.1M -549.4%	$-3.7M

AI Insight: LONA Financial Trends

LeonaBio's Q4 2025 loss spike to -$83M net and -$79M operating income suggests a large one-time charge, but equity recovered to $49M in Q1 2026, masking a persistent cash burn problem.

• Net losses narrowed sharply from -$29M in Q3 2024 to -$7M in Q2–Q3 2025, signaling meaningful operating cost reductions over that stretch.

• Q4 2025 saw a dramatic loss reversal to -$83M net and -$79M operating income, the worst in the observed period, disrupting the improvement trend.

• Equity has eroded from $83M in Q2 2024 to $27M in Q3 2025, a -$56M decline across five quarters, reflecting sustained cash consumption.

• Equity rebounded to $49M in Q1 2026 from $28M in Q4 2025, likely indicating a capital raise rather than operational improvement given continued losses.

⚠ The Q4 2025 charge driving -$83M net loss needs explanation; if non-recurring, underlying burn may be manageable, but recurrence would be critical.

⚠ Operating cash burn remained elevated at -$19M to -$21M in Q4 2025 and Q1 2026 despite no revenue; runway depends entirely on equity raises.

⚠ Q1 2026 equity jump to $49M vs. Q4 2025's $28M warrants monitoring for dilution risk if funded by new share issuance.

AI Insight: LONA Ratio Trends

Data is too sparse for reliable trend analysis — only ROE and ROA are partially populated across a handful of quarters.

• ROE improved from -199.7% in Q3 2024 to -87.1% in Q2 2025, suggesting reduced quarterly losses relative to equity.

• ROA improved from -96.6% in Q2 2024 to -78.4% in Q2 2025, the only quarter with both ROE and ROA data.

• ROE and ROA deteriorated again in Q3 2025 to -98.7% and -88.0% respectively, reversing the Q2 2025 improvement.

⚠ OpMargin, NPM, ROIC, and D/E are entirely absent — capital structure and profitability picture remains largely invisible.

⚠ ROE and ROA going dark in Q4 2025 and Q1 2026 prevents any assessment of the current trajectory.

Get alerted when LONA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LeonaBio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LONA

PERCEPTIVE ADVISORS LLC
$19.1M1,859,322 sh
ADAR1 Capital Management, LLC
$7.5M727,481 sh
ACORN CAPITAL ADVISORS, LLC
$6.5M634,539 sh
Commodore Capital LP
$4.8M464,398 sh
NEA Management Company, LLC
$4.8M464,398 sh
TCG Crossover Management, LLC
$4.7M464,398 sh
Kalehua Capital Management LLC
$4.0M393,701 sh
Spruce Street Capital LP
$3.8M393,701 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.0M194,760 sh
Seven Fleet Capital Management LP
$1.7M164,676 sh

Fund	Value	Shares
PERCEPTIVE ADVISORS LLC	$19.1M	1,859,322
ADAR1 Capital Management, LLC	$7.5M	727,481
ACORN CAPITAL ADVISORS, LLC	$6.5M	634,539
Commodore Capital LP	$4.8M	464,398
NEA Management Company, LLC	$4.8M	464,398
TCG Crossover Management, LLC	$4.7M	464,398
Kalehua Capital Management LLC	$4.0M	393,701
Spruce Street Capital LP	$3.8M	393,701
VANGUARD CAPITAL MANAGEMENT LLC	$2.0M	194,760
Seven Fleet Capital Management LP	$1.7M	164,676

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LONA on your watchlist

Track score changes the day LeonaBio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LONA a good stock to buy?

13F Pro's AI-powered analysis of LeonaBio, Inc. (LONA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LONA are available on the LONA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LONA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LONA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LeonaBio, Inc.'s investment landscape.